Autocrine Control of CD276 by SPARC in Liver Cancer and Its Contribution to Immune Escape and Resistance to Immunotherapy Authors: Mengying Tang, Jing Liu Published: 2026 ABSTRACT ABSTRACTHepatocellular carcinoma (HCC) frequently demonstrates resistance to immunotherapeutic interventions, a phenomenon largely linked to mechanisms of immune escape. Among the modulators of the tumor microenvironment, SPARC (Secreted Protein Acidic and Rich in Cysteine), a matricellular glycoprotein, has been associated with diverse oncogenic processes in multiple cancer types. However, the contribution of SPARC to immune regulation through CD276 signaling remains insufficiently characterized. To clarify this mechanism, we employed the murine Hepa1‐6 hepatoma cell line established from C57BL/6 mice. Functional studies were carried out by genetically altering the expression of SPARC and CD276, followed by comprehensive assessments including Western blot analysis, polymerase chain reaction, flow cytometry, and in vivo tumorigenicity assays. Overexpression of SPARC in HCC cells led to increased CD276 levels through activation of the p65/c‐Myc axis, which also promoted cancer cell stemness. This upregulation impaired the response to immune checkpoint blockade (ICB) therapy, as evidenced by reduced infiltration and activation of CD8 + T cells within the tumor microenvironment. Additionally, increased SPARC‐induced CD276 expression diminished T‐cell activation and proliferation, marked by decreased IFN‐γ production and reduced phosphorylation of ZAP70, a key T‐cell signaling molecule. Our findings underscore the critical role of SPARC in upregulating CD276 in HCC, which contributes to immune suppression and resistance to ICB therapy.Keywords: CD276, hepatocellular carcinoma, immune checkpoint blockade, SPARC, tumor immunosuppression Introduction Hepatocellular carcinoma (HCC) continues to represent a major therapeutic challenge, largely owing to delayed clinical detection and the suboptimal efficacy of standard treatment strategies [1, 2]. Recent advances in immunotherapy, particularly immune checkpoint blockade (ICB) targeting inhibitory axes such as PD‐1/PD‐L1, have introduced promising options for HCC management [3, 4, 5]. By reactivating antitumor immunity, these agents enable immune cells to better recognize and eliminate malignant hepatocytes. Nevertheless, clinical responses to ICB remain heterogeneous among HCC patients, reflecting the presence of diverse molecular networks that orchestrate immune escape and limit therapeutic benefit. In the context of hepatocellular carcinoma (HCC), the tumor microenvironment is orchestrated by multiple regulatory factors, among which the matricellular glycoprotein SPARC (Secreted Protein Acidic and Rich in Cysteine) emerges as a critical determinant with profound effects on tumor biology [6, 7, 8]. Known for its involvement in cellular proliferation, tissue remodeling, and cellular differentiation, SPARC has also been implicated in immune regulation [9, 10, 11]. Studies have suggested that SPARC can influence the tumor microenvironment by modulating the activity and availability of cytokines and growth factors, which in turn affects immune surveillance and tumor immune escape [12, 13, 14]. Consistently, stromal components such as cancer‐associated fibroblasts have been shown to reshape the tumor immune microenvironment by enriching tumor‐associated macrophages and suppressing NK‐cell function, highlighting the broader importance of stromal–immune interactions in cancer immune evasion [15]. The NF‐κB pathway, with p65 as a critical component, is another significant player in the immune response and oncogenesis [16, 17]. It is activated in response to inflammatory cytokines and cellular stress, leading to the transcription of genes that promote cell survival, proliferation, and inflammation [18, 19, 20, 21]. In oncogenic settings, the transcription factor p65 is recognized as a key driver of malignant progression, promoting both uncontrolled proliferation and evasion of apoptosis. Persistent activation of this pathway has been correlated with unfavorable clinical outcomes and reduced survival in patients with hepatocellular carcinoma (HCC) [22, 23]. C‐Myc, a well‐known oncogene, is overexpressed in many cancers, including HCC, where it promotes cell growth, proliferation, and survival [24, 25]. The role of c‐Myc extends to the immune system, where it can influence the expression of various immune checkpoints and cytokines, potentially affecting the tumor's immune microenvironment and the efficacy of ICB therapies [26]. CD276, or B7‐H3, an immune checkpoint molecule, is another critical factor in the immune evasion strategy of tumors. It is often upregulated in HCC and has been associated with inhibition of T‐cell‐mediated cytotoxicity, contributing to the immunosuppressive environment that allows tumors to thrive and evade immune detection. Given the intricate relationships between these molecules and their collective impact on the tumor immune environment and response to therapy, this study aims to dissect the interactions between SPARC, p65, c‐Myc, and CD276 in HCC. Specifically, we will explore how the SPARC/p65 axis may regulate CD276 through mechanisms involving c‐Myc, potentially altering immune evasion strategies and responsiveness to ICB therapy. By understanding these pathways and their interactions, we aim to identify novel therapeutic targets and strategies to enhance the effectiveness of ICB in treating hepatocellular carcinoma. Materials and Methods Cell Lines and Culture Conditions Hepa1‐6 cells, established from a C57BL/6 mouse‐derived hepatocellular carcinoma, were maintained in Dulbecco's Modified Eagle Medium (DMEM, Gibco). The culture medium was supplemented with 10% fetal bovine serum (FBS, Sigma‐Aldrich) as a nutrient source, along with 100 U/ml penicillin and 100 μg/mL streptomycin (Gibco) to prevent bacterial contamination. Cells were incubated under controlled conditions at 37°C in a humidified chamber with 5% CO2 to ensure optimal growth. Genetic Manipulation The coding sequences of SPARC and CD276 were subcloned into the pcDNA3.1(+) expression plasmid (Invitrogen). Hepa1‐6 cells, when reaching approximately 70%–80% confluency, were subjected to transient transfection with these plasmid constructs using Lipofectamine 3000 (Invitrogen) following standard protocols provided by the supplier. For gene silencing experiments, shRNAs specifically targeting p65 and CD276 (Sigma‐Aldrich) were inserted into the pLKO.1 vector. The resulting constructs were subsequently packaged into lentiviral particles in 293 T cells with the aid of a second‐generation packaging system (Sigma‐Aldrich). Western Blotting For protein extraction, cultured cells were disrupted in RIPA lysis buffer (Thermo Fisher Scientific), supplemented with a commercially available cocktail of protease and phosphatase inhibitors (Roche) to preserve protein integrity and phosphorylation states during sample preparation. Protein concentration was determined using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). Equal amounts of protein (30 µg) were separated on 10% SDS‐PAGE gels and transferred to PVDF membranes (Millipore). Following electrophoretic transfer, membranes were blocked in Tris‐buffered saline with Tween‐20 (TBST) supplemented with 5% non‐fat milk for 1 h at ambient temperature. Subsequently, the blots were incubated overnight at 4°C with primary antibodies directed against SPARC, p65, c‐Myc, CD276, and GAPDH (Cell Signaling Technology). After thorough washing, membranes were probed with horseradish peroxidase (HRP)‐conjugated secondary antibodies (Bio‐Rad). Signal detection was achieved using the SuperSignal West Pico PLUS chemiluminescent substrate (Thermo Fisher Scientific) according to the manufacturer's protocol. Quantitative Real‐Time PCR Total RNA was isolated from cultured cells using TRIzol reagent (Invitrogen) according to standard extraction procedures, ensuring preservation of RNA integrity. The concentration and purity of RNA were assessed spectrophotometrically, and 1 µg of high‐quality RNA was subsequently reverse transcribed into complementary DNA (cDNA) with the High‐Capacity cDNA Reverse Transcription Kit (Applied Biosystems). For quantitative gene expression analysis, real‐time PCR assays were performed using PowerUp SYBR Green Master Mix (Applied Biosystems) on a QuantStudio 5 Real‐Time PCR System (Applied Biosystems). Cycling conditions were optimized to enhance amplification efficiency and minimize nonspecific products. Primer pairs specific for SPARC, p65, c‐Myc, CD276, and GAPDH were designed using Primer3 software and validated to ensure the specificity and reproducibility of amplification. GAPDH served as the internal control for normalization of gene expression levels. Chromatin Immunoprecipitation (ChIP) ChIP experiments were performed with the SimpleChIP Enzymatic Chromatin IP Kit (Cell Signaling Technology) according to standardized procedures. Hepa1‐6 cells were treated with 1% formaldehyde for 10 min at room temperature to covalently cross‐link DNA–protein complexes. The chromatin was then subjected to controlled enzymatic digestion to achieve appropriate shearing, followed by immunoprecipitation using 5 µg of antibodies specific for c‐Myc or p65 (Cell Signaling Technology). Normal rabbit IgG was included as an isotype control to assess nonspecific binding. DNA recovered from the immunoprecipitated complexes was subsequently pcurified and quantified by real‐time PCR employing primers spanning the promoter region of CD276 to determine transcription factor occupancy. Flow Cytometry Flow cytometry was employed to evaluate both surface and intracellular immune markers. For surface staining, Fc receptor‐mediated background was minimized by pre‐incubating cells with Human TruStain FcX (BioLegend) for 10 min at 4°C, followed by staining with a panel of fluorescently tagged antibodies against CD276, CD8, CD4, CD107a, CD137, and IFN‐γ (BD Biosciences). Incubations were carried out for 30 min at 4°C under light‐protected conditions. For intracellular staining, cells were chemically fixed and permeabilized using the Cytofix/Cytoperm Kit (BD Biosciences), which facilitates antibody access to cytoplasmic and nuclear antigens. Flow cytometric data were acquired using a BD LSRFortessa instrument, and subsequent data processing and quantitative analyses were performed with FlowJo software (version 10). In Vivo Tumor Growth Assay C57BL/6 mice aged 6–8 weeks were purchased from The Jackson Laboratory and maintained under specific pathogen‐free conditions in the animal facility of Hengyang Medical School, University of South China. Each animal received a subcutaneous injection of 1 × 106 Hepa1‐6 hepatoma cells suspended in sterile PBS into the flank region. Tumor growth was monitored every 3 days, and volume was calculated using the formula: Volume = (Length × Width2)/2. Mice were divided into groups and treated with control IgG or anti‐PD‐L1 antibodies (10 mg/kg, BioXCell) twice weekly. Statistical Analysis Statistical analyses were conducted using GraphPad Prism (version 8). Group differences were first assessed by one‐way analysis of variance (ANOVA), and when overall significance was achieved, Tukey's post hoc test was applied to evaluate pairwise comparisons. All numerical data are reported as mean ± SEM to indicate variability within each group. Statistical significance was defined at a cutoff of p < 0.05. Results SPARC Overexpression Modulates the Efficacy of ICB Therapy via the p65/c‐Myc/CD276 Axis Immune checkpoint blockade (ICB) has emerged as a pivotal immunotherapeutic strategy that functions by interfering with inhibitory signaling cascades such as the PD‐1/PD‐L1 axis. By relieving T cells from checkpoint‐mediated suppression, these interventions are intended to reinvigorate cytotoxic lymphocyte activity and thereby enhance antitumor immune responses. Over the past decade, blockade of the PD‐1/PD‐L1 pathway has demonstrated remarkable clinical success in several malignancies, highlighting its potential as a broadly applicable therapeutic approach. To evaluate the relevance of this mechanism in hepatocellular carcinoma (HCC), we established a murine model using Hepa1‐6 tumor‐bearing mice. Within this system, the effect of PD‐L1 neutralization was systematically examined, providing a foundation for investigating whether modulation of SPARC expression could further influence therapeutic outcome. Additionally, a subset of these mice was treated with periodic overexpression of SPARC. Tumor growth curves indicate that SPARC overexpression significantly diminished the efficacy of anti‐PD‐L1 therapy (Figure 1A), suggesting that SPARC may reduce the therapeutic effect of ICBs. Immunoblot analysis of tumor tissues from SPARC‐overexpressing mice showed a significant increase in nuclear p65 expression (Figure 1B). Flow cytometry analysis of sorted circulating tumor cells, specifically epithelial cell marker EpCAM‐positive and leukocyte marker CD45‐negative cells, revealed an upregulation of CD276 post‐SPARC overexpression (Figure 1C). In vitro, after activating NF‐κB/p65 signaling in Hepa1‐6 cells with phorbol 12‐myristate 13‐acetate (PMA), an increase in CD276 expression was observed (Figure 1D). However, chromatin immunoprecipitation (ChIP) assays showed increased enrichment of c‐Myc, but not p65, at the CD276 promoter after SPARC treatment (Figure 1E). We further investigated whether p65 influenced c‐Myc protein stability. Following cycloheximide treatment to inhibit de novo protein synthesis, c‐Myc protein levels declined more rapidly in p65‐knockdown cells than in control cells, indicating that p65 depletion accelerates c‐Myc protein degradation (Figure 1F). RT‐PCR analysis confirmed a significant increase in CD276 mRNA expression following c‐Myc overexpression (Figure 1G). Collectively, these data suggest the existence of a SPARC/p65/c‐Myc/CD276 axis in tumors. Our findings also indicate that c‐Myc overexpression enhances the stem cell‐like properties of tumor cells (Figure 1H). SPARC overexpression attenuates the efficacy of ICB via the inhibition of the p65/c‐Myc/CD276 axis in tumor cells. (A) Growth curves of tumors in control, ICB treated, SPARC OE (overexpression), and SPARC OE + ICB treated mice, showing that SPARC OE significantly reduces the efficacy of ICB therapy (***p < 0.001 compared to anti‐PD‐L1 + SPARC OE group). (B) Immunoblot analysis of p65 expression in nuclear and cytoplasmic fractions of tumor cells from control and SPARC OE mice. Lamin B was used as the nuclear loading control, whereas GAPDH was used as the cytoplasmic loading control. (C) Flow cytometry gating for EpCAM+/CD45− tumor cells, followed by analysis of CD276 expression levels across different groups. (D) Flow cytometry analysis of CD276 expression in Hepa1‐6 cells treated with phorbol 12‐myristate 13‐acetate (PMA) to activate NF‐κB/p65 signaling. (E) ChIP assays showing relative enrichment of c‐Myc and p65 on the CD276 promoter. Following SPARC treatment, c‐Myc enrichment at the CD276 promoter was significantly increased compared with the vector control (***p < 0.001), whereas no significant changes were observed for p65 or IgG controls. (F) Protein stability analysis of c‐Myc in control and sh‐p65 knockdown cells over 6 h with CHX treatment, using GAPDH as a loading control. Compared with control cells, p65 knockdown accelerated the reduction of c‐Myc protein levels after CHX treatment, indicating enhanced c‐Myc degradation in sh‐p65 cells. (G) RT‐PCR analysis of CD276 mRNA expression in control and c‐Myc OE (overexpression) cells, showing a significant increase in c‐Myc OE cells (***p < 0.001 compared to NC group). (H) Flow cytometry analysis of tumor stem cell markers CD44, CD271, and GPR49 in tumor‐bearing Hepa1‐6 cells overexpressing c‐Myc on Day 25. Overexpression of CD276 in Tumors Reduces Infiltration and Activation of CD8 + T Cells To investigate the functional relevance of CD276 in shaping the tumor–immune interface, we engineered Hepa1‐6 hepatoma cells to stably overexpress CD276 (Figure 2A). These modified tumor cells (CD276 OE) were subsequently inoculated into immunocompetent BALB/c mice to establish subcutaneous tumor models. Compared with control tumors, those derived from CD276‐overexpressing cells exhibited accelerated growth kinetics, suggesting that CD276 confers a tumor‐promoting advantage in vivo (Figure 2B). Overexpression of CD276 in tumors reduces infiltration and activation of CD8 + T cells. (A) Flow cytometric analysis of CD276 expression in Hepa1‐6 cells with CD276 overexpression. (B) Tumor growth in mice inoculated with wild‐type Hepa1‐6 cells and CD276 overexpressing Hepa1‐6 cells, showing accelerated growth in the CD276 OE group (***p < 0.001 indicates a statistically significant difference compared with the control group). (C) Flow cytometry measurement of the percentage of CD3 + /CD8 + T cells infiltrating tumors in each group, showing a reduction in the CD276 OE group (***p < 0.001 indicates a statistically significant difference compared with the control group). (D) Analysis of IFN release by CD3 + /CD8 + T cells in tumors from each group, indicating decreased IFN expression in the CD276 OE group (***p < 0.001 indicates a statistically significant difference compared with the control group). (E) Proportion of CD107+ and CD137+ cells within the tumor CD8 + T cells analyzed by flow cytometry, showing reduced activation in the CD276 OE group (***p < 0.001 indicates a statistically significant difference compared with the control group). Comprehensive immunophenotyping by flow cytometry further revealed striking alterations within the tumor microenvironment. Specifically, the proportion of infiltrating CD3 + CD8 + T lymphocytes was markedly reduced in CD276 OE tumors relative to controls (Figure 2C). This decline in cytotoxic T‐cell presence was accompanied by diminished production of effector cytokines, including IFN‐γ (Figure 2D), consistent with a blunted antitumor immune response. In addition to reduced infiltration, CD8 + T cells present within CD276 OE tumors also displayed impaired functional activation. Flow cytometric analysis demonstrated that the frequency of CD8 + T cells expressing activation‐associated molecules such as CD137 and CD107 was substantially decreased (Figure 2E). These findings point to a dual effect of CD276 upregulation, both limiting the recruitment of cytotoxic T cells into the tumor bed and suppressing their effector function once present. Taken together, our results demonstrate that heightened CD276 expression in tumors creates a profoundly immunosuppressive environment. By restricting the infiltration of CD8 + T cells and simultaneously attenuating their activation state, CD276 overexpression enables tumor cells to evade immune elimination, thereby facilitating more aggressive tumor progression. Elevated Tumor CD276 Restrains Proliferation and Activation of CD8 + T Lymphocytes In Vitro In order to clarify how elevated CD276 expression influences T‐cell behavior in vitro, CD8 + T lymphocytes were purified from OT‐1 transgenic mice and subsequently stimulated with OVA peptide before being placed in co‐culture with Hepa1‐6 tumor cells engineered to overexpress CD276. Tracking cell proliferation through CFSE dilution assays revealed that contact with CD276‐high tumor cells markedly impaired the expansion of activated CD8 + T cells when compared with parallel cultures exposed to control tumor cells (Figure 3A). These observations indicate that aberrant CD276 expression in tumor cells exerts a suppressive effect on the proliferative capacity of cytotoxic T lymphocytes. In vitro experiments showing the impact of high CD276 expression on CD8 + T cell proliferation and activation. (A) Flow cytometry analysis of CFSE dilution in CD8 + T cells isolated from OT‐1 mice after activation with OVA antigen and co‐culture with CD276 overexpressing Hepa1‐6 cells. ***p < 0.001 indicates a statistically significant difference compared to the nc (negative control) group. (B) After expressing OVA in Hepa1‐6 cells and CD276 OE Hepa1‐6 cells, co‐culture with OT‐1 derived CD8 + T cells, and flow cytometry analysis of the killing effect on Hepa1‐6 cells. ***p < 0.001 indicates a statistically significant difference compared to the nc group. (C) Flow cytometry analysis of IFN‐positive rates in CD8 + T cells from OT‐1 mice co‐cultured with OVA‐expressing Hepa1‐6 cells or CD276/OVA OE Hepa1‐6 cells. ***p < 0.001 indicates a statistically significant difference compared to the nc group. (D) Flow cytometry analysis of ZAP70 phosphorylation (p‐ZAP70) in CD8 + T cells from OT‐1 mice co‐cultured with OVA‐expressing Hepa1‐6 cells or CD276/OVA OE Hepa1‐6 cells. ***p < 0.001 indicates a statistically significant difference compared to the nc group. To further explore the cytotoxic potential of these antigen‐specific T cells, we generated Hepa1‐6 cells simultaneously overexpressing both CD276 and OVA (CD276/OVA OE). When these engineered tumor cells were co‐cultured with OT‐1 T cells, the killing efficiency of T cells was noticeably compromised relative to their activity against OVA‐only tumor cells (Figure 3B). This reduction in tumor cell death underscores the inhibitory role of CD276 in attenuating T‐cell effector function even under conditions of cognate antigen recognition. In addition to proliferation and cytotoxicity, molecular readouts of T‐cell activation were also assessed. Co‐culture with CD276/OVA OE tumor cells resulted in diminished production of IFN‐γ and attenuated phosphorylation of ZAP70, a critical signaling kinase downstream of the TCR complex (Figures 3C,D). Together, these results highlight that heightened CD276 expression not only restricts T‐cell proliferation but also interferes with their activation cascade, thereby dampening TCR signaling and limiting the antitumor response of CD8 + T lymphocytes in vitro. Knocking Down p65 Inhibits Tumor Progression Induced by High SPARC Expression To further explore the regulatory mechanism of the SPARC/p65 axis in tumor progression, we knocked down p65 in SPARC‐overexpressing cells. Tumor inoculation experiments showed that p65 knockdown inhibited tumor progression induced by SPARC overexpression during ICB treatment (Figure 4A). Examination of tumor specimens harvested from the inoculated mice demonstrated that p65 silencing markedly attenuated SPARC‐induced CD276 upregulation (Figure 4B), indicating that p65 mediates the association between SPARC overexpression and increased CD276 expression. Moreover, flow cytometric assessment revealed that p65 knockdown restored immune cell recruitment, as evidenced by an increased proportion of CD3 + CD8 + T lymphocytes within the tumor microenvironment (Figure 4C). Because Foxp3+ regulatory T cells are major contributors to immunosuppression within the tumor microenvironment and may influence the response to immune checkpoint blockade, we next examined whether disruption of the SPARC/p65 axis altered the tumor‐infiltrating Treg compartment. The proportion of CD4 + T cells did not change significantly (Figure 4D). Similarly, neither the proportion of Foxp3+ Tregs nor the frequency of Ki67+ proliferating Foxp3+ Tregs was significantly altered (Figures 4E,F). These findings suggest that the SPARC/p65 signaling cascade primarily affects cytotoxic CD8 + T lymphocytes, while exerting minimal effects on CD4 + T cells, Foxp3+ Treg infiltration, or Treg proliferation. p65 knockdown reverses SPARC‐induced CD276 upregulation and restores CD8 + T‐cell infiltration without significantly affecting tumor‐infiltrating Tregs or Treg proliferation. (A) Tumor growth curves for control, anti‐PD‐L1‐treated, SPARC OE + anti‐PD‐L1, and SPARC OE + sh‐p65 + anti‐PD‐L1 groups. (B) Flow cytometry analysis of CD276 expression levels in tumor cells from tumor‐bearing mice. (C) Flow cytometry analysis of tumor‐infiltrating CD8 + T cells in different groups. ***p < 0.001 indicates a statistically significant difference compared with the SPARC OE group. (D) Flow cytometry analysis of CD4 + T‐cell levels in tumors from different groups. ns indicates no significant difference compared with the SPARC OE group. (E) Flow cytometry analysis of tumor‐infiltrating Foxp3+ Tregs in different groups. ns indicates no significant difference compared with the SPARC OE group. (F) Flow cytometry analysis of Ki67 expression in tumor‐infiltrating Foxp3+ Tregs from different groups. ns indicates no significant difference compared with the SPARC OE group. Discussion The collective data from this study reveal a complex regulatory network involving SPARC, p65, c‐Myc, and CD276, which together shape the immunological and structural characteristics of the tumor milieu in hepatocellular carcinoma (HCC). Rather than exerting isolated effects, these molecules operate in concert to influence tumor progression and immune responsiveness. By integrating results obtained from both animal models and cell‐based assays, we were able to map the signaling cascade through which SPARC promotes tumor immune escape, ultimately linking extracellular matrix remodeling with intracellular transcriptional programs that regulate T‐cell function. A major conclusion from our work is that heightened SPARC expression undermines the therapeutic benefit of PD‐L1 blockade. Mechanistically, SPARC amplifies nuclear accumulation of p65, which in turn drives c‐Myc‐dependent induction of CD276. The combined effect of this signaling axis is a substantial weakening of antitumor immunity, manifested as a decrease in both the presence and functional competence of CD8+ cytotoxic T cells within tumor lesions. Thus, instead of acting solely at the level of tumor cell biology, SPARC exerts broader immunomodulatory control by establishing a microenvironment less permissive to T‐cell infiltration and by restraining the activation of those T cells that do reach the tumor site. Furthermore, the direct manipulation of this pathway, through the knockdown of p65, revealed a reversal of these effects. Knocking down p65 not only decreased CD276 expression but also restored T cell infiltration and activity. This suggests that targeting the SPARC/p65/CD276 axis could potentially enhance the response to ICB therapy by alleviating immune suppression mediated by CD276. Interestingly, while the SPARC/p65/CD276 axis predominantly affects CD8 + T cell dynamics, our results indicate that it does not significantly impact the population or function of CD4 + T cells or regulatory T cells (Tregs). This specificity underscores the potential for targeted therapies that modulate this axis without broadly affecting other components of the immune system, a feature that is of particular importance because it allows the mitigation of adverse immune‐related reactions while simultaneously enhancing the overall effectiveness of therapeutic interventions. The implications of these findings are profound, suggesting that the modulation of specific signaling pathways in HCC can significantly impact the response to immunotherapy. By elucidating the role of SPARC in mediating immune evasion through p65 and CD276, our study provides a potential target for enhancing the efficacy of ICB therapy in HCC. However, translating these findings into clinical practice requires careful consideration of the molecular heterogeneity of HCC and the diverse immune landscapes across different patients. Several limitations should be acknowledged. Although our data suggest an association between SPARC expression, p65 activation, c‐Myc stability, and CD276 upregulation, the present study does not fully establish the direct molecular mechanisms connecting these events. The accelerated loss of c‐Myc protein following p65 knockdown suggests that p65 may indirectly maintain c‐Myc protein stability through downstream effectors that protect c‐Myc from proteolytic degradation. Accordingly, depletion of p65 may disrupt these stabilizing mechanisms and thereby facilitate c‐Myc degradation. However, this proposed mechanism remains speculative, and the specific downstream mediators responsible for regulating c‐Myc stability require further investigation. The receptor‐level mechanism by which SPARC activates p65 signaling also remains to be determined. In addition, we did not perform ChIP assays to test whether p65 directly binds to the c‐Myc promoter, nor did we conduct luciferase reporter assays to confirm that c‐Myc directly activates CD276 transcription. Therefore, the proposed SPARC/p65/c‐Myc/CD276 pathway should be interpreted as a putative regulatory axis supported by the current functional and correlative evidence rather than as a fully validated linear signaling cascade. Future studies using receptor‐blocking approaches, promoter‐occupancy assays, protein‐interaction analyses, and CD276 promoter‐reporter systems will be required to define this mechanism more precisely. Three‐dimensional tissue‐clearing and whole‐organ imaging approaches may also help define the spatial relationship between CD276‐high tumor cells and infiltrating immune cells within intact tumor tissues, thereby providing additional spatial validation of the proposed immunosuppressive microenvironment [27]. Overall, the findings from our investigation contribute additional evidence to the expanding framework of knowledge that supports the development of combination therapies targeting not only the PD‐1/PD‐L1 axis but also the molecular mechanisms that regulate immune checkpoints and T cell suppression within the tumor microenvironment. Subsequent investigations will need to be directed toward the clinical evaluation of inhibitors targeting the SPARC/p65/CD276 axis in conjunction with established ICB therapies to determine their potential to improve patient outcomes in HCC. Author Contributions Mengying Tang: software; methodology; data curation; investigation; validation; visualization; formal analysis. Jing Liu: conceptualization; methodology; project administration; resources; writing – review and editing; writing – original draft; funding acquisition; supervision. Funding The authors have nothing to report. Ethics Statement This study does not involve human participants; therefore, informed consent and permissions statements are not applicable. All experiments were carried out following established institutional and international guidelines for biomedical research. Animal‐related procedures performed during this study received approval from the Ethics Committee of The First Affiliated Hospital, Hengyang Medical School, University of South China. All procedures strictly adhered to the internationally recognized Guide for the Care and Use of Laboratory Animals as well as relevant national regulations. The study also included cell‐based experiments, which were performed under strict ethical oversight and in conformity with recognized scientific standards. Data Availability Statement All data generated or analyzed during this study are included in the published article and its supplementary information materials. References Associated Data Data Availability Statement All data generated or analyzed during this study are included in the published article and its supplementary information materials.